Blood Extraction Platform | Tenderlake

Blood Extraction Platform

Contract Value:
GBP 525K -
Notice Type:
Contract Notice
Published Date:
21 October 2024
Closing Date:
21 November 2024
Location(s):
UKK SOUTH WEST (ENGLAND) (UK UNITED KINGDOM)
Description:
An opportunity exists for suppliers to provide a high throughput DNA extraction platform for the Bristol Genetics laboratory, capable of extracting high yields of genomic DNA from venous blood samples.
Blood Extraction Platform.
This contract is for 6 years with an options 1 year extension. Full details are provided in the Invitation To Tender pack. This is provided in the SAP Ariba portal.
In 2018 NHSE commissioned Genomic Laboratory Hubs (GLHs) for the delivery of high-quality, efficient, and centralised genomic services. The South West GLH is hosted at NBT, all core rare disease, cancer testing and specialised rare disease testing in cardiology, renal and neurology is provided from the Bristol Genetics laboratory (BGL).
The purpose of this notice is to alert potential suppliers to an opportunity to provide a high throughput DNA extraction platform capable of extracting DNA from venous blood where sample volumes are greater than 2ml and be able to produce a high yield of high molecular weight (>48kb) genomic DNA to BGL. The system must produce minimum DNA yields which average between 40 and 100 micrograms of DNA from 2-10ml of human blood. This is key to ensure that the platform can meet the requirements of our Facioscapulohumeral muscular dystrophy (FSHD) service for which 95% of diagnoses are made through genomic testing using Southern Blotting.
The total funding available for this capital equipment procurement is £350,000 (inclusive of VAT) however reagent and consumable costs will also be taken into consideration when assessing the Whole Life Cost of the award. Therefore, the estimated total value is inclusive of this.

Additional requirements include;
- The platform should be high throughput with flexibility in batch sizes for efficient use. These should range from a single sample to maximum batch size.
- The system must allow the use of a variety of tube types in which the extracted DNA can be collected or eluted into, in particular 2ml screw-cap tubes and 2D barcoded tubes (e.g. fluidX 0.7ml tubes).
- Cross-contamination of samples during automated processing must be shown to be absent
- The system must incorporate barcode scanning and be able to record the barcode labels of both primary tubes and DNA output tubes in a log or database.
- The system must be able to use barcoding data to match the input tube with the output tube and complete elution of DNA according to this information.
- The system must be capable of automating extraction procedure to a level where 'walkaway' operation is facilitated
- The system must be capable of sampling from the primary tube starting material (blood)- avoiding the need to manually aspirate from the primary sample tube
- The system must be enclosed in such a way to protect the operators.
Download full details as .pdf
The Buyer:
BRISTOL & WESTON NHS PURCHASING CONSORTIUM
Additional information:
Link:
View Notice Source
Link:
Download Full Notice as PDF
CPV Code(s):
33100000 - Medical equipments